

Express Mail No. <u>EV 622 502 632 US</u> Docket No. <u>3828-4000US1</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Gelber

Confirmation No.

9860

Serial No.:

09/995,522

Group Art Unit:

1642

Filed:

November 28, 2001

Examiner:

L. Helms

For:

Myeloma Cell And Ovarian Cancer Cell Surface

Glycoprotein, Antibodies Thereto, and Uses Thereof

ISSUE FEE TRANSMITTAL

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Applicant hereby submits Form PTOL-85 Part B. The Commissioner is hereby authorized to charge any fees required in connection with this submission to Deposit Account No. 13-4500, Order No. 3828-4000US1. A copy of this sheet is enclosed.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: November 9, 2005

Melissa B. Wenk

Registration No. 53,759

Correspondence Address:

Morgan & Finnegan, L.L.P. 3 World Financial Center New York, New York 10281-2101 (212) 415-8700 Telephone (212) 415-8701 Facsimile

27123

TOUSTOMER NUMBERT

-14-05

PART B - FEE(S) TRANSMITTAL

Complete and sent this form, together with applicable fee(s), to: Mail NOV 0 9 2005

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450


or Fax

(571) 273-2885

INSTACTION FEE (if required). Blocks 1 through 5 should be completed where appropriate and recorrespondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications. Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) 7590 08/10/2005 Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below. MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053 11/15/2005 MAHMED2 00000060 134500 09995522 (Depositor's name) 01 FC:2501 700.00 DA 300.00 DA 02 FC:1504 (Date 03 FC:8001 6.00 DA FIRST NAMED INVENTOR APPLICATION NO. FILING DATE ATTORNEY DOCKET NO. CONFIRMATION NO. 09/995,522 11/28/2001 Cohava Gelber 3828-4000US1 TITLE OF INVENTION: MYELOMA CELL AND OVARIAN CANCER CELL SURFACE GLYCOPROTEINS, ANTIBODIES THEREOF, AND USES THEREOF ISSUE FEE APPLN. TYPE SMALL ENTITY PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE \$700 nonprovisional YES \$300 \$1000 11/10/2005 **EXAMINER** ART UNIT CLASS-SUBCL ASS 1642 YAO, LEI 424-133100 Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Finnegan LLP 2. For printing on the patent front page, list Morgan & (1) the names of up to 3 registered patent attorneys ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (B) RESIDENCE: (CITY and STATE OR COUNTRY) (A) NAME OF ASSIGNEE Molecular Discoveries, L.L.C. New York, New York Please check the appropriate assignee category or categories (will not be printed on the patent): 🔲 Individual 📮 Corporation or other private group entity 🚨 Government 4a. The following fee(s) are enclosed: 4b. Payment of Fee(s): A check in the amount of the fee(s) is enclosed. X Issue Fee Payment by credit card. Form PTO-2038 is attached. Publication Fee (No small entity discount permitted) The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 13-4500 (enclose an extra copy of this form). Advance Order - # of Copies 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ■ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. November Authorized Signature Date <u>Melissa</u> В. Wenk Typed or printed name Registration No.

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Gelber

Confirmation No.

9860

Serial No.:

09/995,522

Group Art Unit:

1642

Filed:

November 28, 2001

Examiner:

L. Helms

For:

Myeloma Cell And Ovarian Cancer Cell Surface Glycoprotein, Antibodies Thereto, and Uses Thereof

EXPRESS MAIL CERTIFICATE

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

I hereby certify that the following attached papers and fee

- 1. Issue Fee Transmittal (w/ duplicate)
- 2. Form PTOL-85 Part B (w/ duplicate)
- 3. Return receipt postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on November 9, 2005 and is addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Melissa Wenk

(Typed or printed name of person mailing papers and fee)

(Signature of person mailing papers and fee)

Correspondence Address:

Morgan & Finnegan, L.L.P. 3 World Financial Center New York, New York 10281-2101 (212) 415-8700 Telephone (212) 415-8701 Facsimile